The sphingosine-1-phosphate (S1P) receptor modulator, fingolimod (FTY720), has been used for the treatment of patients with relapsing forms of multiple sclerosis, but atrioventricular (AV) conduction block have been reported in some patients after the first dose. The underlying mechanism of this AV node conduction blockade is still not well-understood. In this study, we hypothesize that expression of this particular arrhythmia might be related to a direct effect of FTY720 on AV node rather than a parasympathetic mimetic action. We, therefore, investigated the effect of FTY720 on AV nodal, using in vitro rat model preparation, under both basal as well as ischaemia/reperfusion conditions. We first look at the expression pattern of S1P receptors on the AV node using real-time PCR. Although all three S1P receptor isoforms were expressed in AVN tissues, S1P1 receptor isoform expression level was higher than S1P2 and S1P3. The effect of 25 nM FTY720 on cycle length (CL) was subsequently studied via extracellular potentials recordings. FTY720 caused a mild to moderate prolongation in CL by an average 9% in AVN (n = 10, P < 0.05) preparations. We also show that FTY720 attenuated both ischaemia and reperfusion induced AVN rhythmic disturbance. To our knowledge, these remarkable findings have not been previously reported in the literature, and stress the importance for extensive monitoring period in certain cases, especially in patients taking concurrently AV node blocker agents.

Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Cardiovascular Diseases International Clinical Research Center St Anne's University Hospital and Masaryk University Brno Czech Republic

Department of Medical Physics and Biophysics Faculty of Medicine Pavol Jozef Safarik University Kosice Slovak Republic

Department of Pharmacology University of Oxford Oxford and Institute of Cardiovascular Sciences UK

Egom Clinical and Translational Research Services Halifax NS Canada

Zobrazit více v PubMed

Kappos L, Radue EW, O'Connor P, et al A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362: 387–401. PubMed

Schmouder R, Serra D, Wang Y, et al FTY720: placebo‐controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006; 46: 895–904. PubMed

DiMarco JP, O'Connor P, Cohen JA, et al First‐dose effects of fingolimod: pooled safety data from three phase 3 studies. Mult Scler. 2014; 3: 629–38. PubMed

Gialafos E, Gerakoulis S, Grigoriou A, et al Intermittent atrioventricular block following fingolimod initiation. Case Rep Neurol Med. 2014; 2014: 191305. PubMed PMC

Tellez JO, Dobrzynski H, Greener ID, et al Differential expression of ion channel transcripts in atrial muscle and sinoatrial node in rabbit. Circ Res. 2006; 99: 1384–93. PubMed

Liu J, Dobrzynski H, Yanni J, et al Organisation of the mouse sinoatrial node: structure and expression of HCN channels. Cardiovasc Res. 2007; 73: 729–38. PubMed

Cohen JA, Barkhof F, Comi G, et al Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362: 402–15. PubMed

Karliner JS. Sphingosine kinase regulation and cardioprotection. Cardiovasc Res. 2009; 82: 184–92. PubMed PMC

Peters SLM, Alewijnse AE. Sphingosine‐1‐phosphate signaling in the cardiovascular system. Curr Opin Pharmacol. 2007; 7: 186–92. PubMed

Egom EE, Ke Y, Solaro RJ, et al Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine‐1‐phosphate and bradykinin signalling. Prog Biophys Mol Biol. 2010; 103: 142–7. PubMed PMC

Egom EE, Ke Y, Musa H, et al FTY720 prevents ischemia/reperfusion injury‐associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol. 2010; 48: 406–14. PubMed PMC

Egom EE, Mohamed TM, Mamas MA, et al Activation of Pak1/Akt/eNOS signaling following sphingosine‐1‐phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol. 2011; 301: H1487–95. PubMed PMC

Mullershausen F, Zecri F, Cetin C, et al Persistent signaling induced by FTY720‐phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol. 2009; 5: 428–34. PubMed

Olshansky B, Sabbah HN, Hauptman PJ, et al Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation. 2008; 118: 863–71. PubMed

Gold R, Comi G, Palace J, et al ; FIRST Study Investigators . Assessment of cardiac safety during fingolimod treatment initiation in a real‐world relapsing multiple sclerosis population: a phase 3b, open‐label study. J Neurol. 2014; 261: 267–76. PubMed PMC

Koyrakh L, Roman MI, Brinkmann V, et al The heart rate decrease caused by the sphingosine 1‐phosphate receptor agonist FTY720 results from activation of the G protein‐gated potassium channel IKACh. Am J Transplant. 2005; 5: 529–36. PubMed

Sanna MG, Liao J, Jo E, et al Sphingosine 1‐phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004; 279: 13839–48. PubMed

Brinkmann V. Sphingosine 1‐phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007; 115: 84–105. PubMed

Kurachi Y. G protein regulation of cardiac muscarinic potassium channel. Am J Physiol. 1995; 269: C821–30. PubMed

Yagi Y, Nakamura Y, Kitahara K, et al Analysis of onset mechanisms of a sphingosine 1‐phosphate receptor modulator fingolimod‐induced atrioventricular conduction block and QT‐interval prolongation. Toxicol Appl Pharmacol. 2014; 281: 39–47. PubMed

Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug‐induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol. 2008; 154: 1528–37. PubMed PMC

Drici MD, Diochot S, Terrenoire C, et al The bee venom peptide tertiapin underlines the role of I(KACh) in acetylcholine‐induced atrioventricular blocks. Br J Pharmacol. 2000; 131: 569–77. PubMed PMC

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy